搜尋結果
於第二孕期及第三孕期接種。然而，從全球使用不活化流感疫苗（包括三價不活化流感疫苗Vaxigrip） 的數據來看，不活化流感疫苗對胎兒及母體並無任何不良影響。 四個臨床研究第二孕期及第三孕期的懷孕婦女接種三價不活化流感疫苗 Vaxigrip （超過 5000
2019年3月22日 · Background: A quadrivalent split-virion inactivated influenza vaccine (VaxigripTetra™, Sanofi Pasteur; IIV4) containing two A strains (H1N1 and H3N2) and B strains from both lineages (Victoria and Yamagata) was approved in Europe in 2016 for individuals aged ≥ 3 years.
VaxigripTetra™ (IIV4; Sanofi Pasteur) is a quadrivalent split-virion influenza vaccine approved in Europe in 2016 for individuals ≥ 3 years of age. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®).
Vaxigrip Tetra is indicated for active immunisation of adults and children from 6 months of age and older for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine. 4.2 DOSE AND METHOD OF ADMINISTRATION .
2018年3月8日 · This review describes the results obtained from seven phase III clinical trials evaluating the immunogenicity, safety, and lot-to-lot consistency of a new quadrivalent split-virion influenza vaccine (Vaxigrip Tetra ®) formulated by adding a second B strain to the
Vaxigrip Tetra wird angewendet zur aktiven Immunisierung von Erwachsenen und Kindern ab. 6 Monate zur Vorbeugung einer echten Virusgrippe (Influenza), die durch die beiden Influenza-A-Virussubtypen und die beiden Influenza-B-Virussubtypen verursacht wird, gegen die der Impfstoff gerichtet ist.
2017年11月27日 · VaxigripTetra™ (IIV4; Sanofi Pasteur) is a quadrivalent split-virion influenza vaccine approved in Europe in 2016 for individuals ≥ 3 years of age. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®).
